Home : DrugWatch : Valium : Wikipedia : Anticonvulsant

Wikipedia - Anticonvulsant

The anticonvulsants are a diverse group of pharmaceuticals used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder, since many seem to act as mood stabilizers. The goal of an anticonvulsant is to suppress the rapid and excessive firing of neurons that start a seizure. Failing this, an effective anticonvulsant would prevent the spread of the seizure within the brain and offer protection against possible excitotoxic effects that may result in brain damage. Some studies have site that anticonvulsants themselves are linked to lowered IQ in children.[1] However these studies may be moot given the significant risk epileptiform seizures pose to children and the distinct possibility of death and devastating neurological sequela secondary to seizures. Anticonvulsants are more accurately called antiepileptic drugs (abbreviated "AEDs"), sometimes referred to as antiseizure drugs. While an anticonvulsant is a fair description of AEDs, it neglects to differentiate the difference between convulsions and epilepsy. Convulsive non-epileptic seizures are quite common and these types of seizures will not have any response to an antiepileptic drug. In epilepsy an area of the cortex is typically hyperirritable that can often be confirmed by completing an EEG. Antiepileptic drugs function to help reduce this area of irritability and thus prevent epileptiform seizures.

The major molecular targets of marketed anticonvulsant drugs are voltage-gated sodium channels and components of the GABA system, including GABAA receptors, the GAT-1 GABA transporter, and GABA transaminase.[2] Additional targets include voltage-gated calcium channels, SV2A, and a2d. [3][4].


Some anticonvulsants have shown antiepileptogenic effects in animal models of epilepsy. That is, they either prevent the expected development of epilepsy or can halt or reverse the progression of epilepsy. However, no drug has been shown to prevent epileptogenesis (the development of epilepsy after an injury such as a head injury) in human trials.[5]

Contents

[edit] Approval

The usual method of achieving approval for a drug is to show it is effective when compared against placebo, or that it is more effective than an existing drug. In monotherapy (where only one drug is taken) it is considered unethical by most to conduct a trial with placebo on a new drug of uncertain efficacy. This is because untreated epilepsy leaves the patient at significant risk of death. Therefore, almost all new epilepsy drugs are initially approved only as adjunctive (add-on) therapies. Patients whose epilepsy is currently uncontrolled by their medication (i.e., it is refractory to treatment) are selected to see if supplementing the medication with the new drug leads to an improvement in seizure control. Any reduction in the frequency of seizures is compared against a placebo.[5]

Once there is confidence that a drug is likely to be effective in monotherapy, trials are conducted where the drug is compared to an existing standard. For partial-onset seizures, this is typically carbamazepine. Despite the launch of over ten drugs since 1990, no new drug has been shown to be more effective than the older set, which includes carbamazepine, valproate and phenytoin. The lack of superiority over existing treatment, combined with lacking placebo-controlled trials, means that few modern drugs have earned FDA approval as initial monotherapy. In contrast, Europe only requires equivalence to existing treatments, and has approved many more. Despite their lack of FDA approval, the American Academy of Neurology and the American Epilepsy Society still recommend a number of these new drugs as initial monotherapy.[5]

[edit] Drugs

In the following list, the dates in parentheses are the earliest approved use of the drug.

[edit] Aldehydes

Main article: Aldehydes

  • Paraldehyde (1882). One of the earliest anticonvulsants. Still used to treat status epilepticus, particularly where there are no resuscitation facilities.

[edit] Aromatic allylic alcohols

  • Stiripentol (2001 - limited availability). Indicated for the treatment of severe myoclonic epilepsy in infancy (SMEI).

[edit] Barbiturates

Main article: Barbiturates

Barbiturates are drugs that act as central nervous system (CNS) depressants, and by virtue of this they produce a wide spectrum of effects, from mild sedation to anesthesia. The following are classified as anticonvulsants:

Phenobarbital was the main anticonvulsant from 1912 till the development of phenytoin in 1938. Today, phenobarbital is rarely used to treat epilepsy in new patients since there are other effective drugs that are less sedating. Phenobarbital sodium injection can be used to stop acute convulsions or status epilepticus, but a benzodiazepine such as lorazepam, diazepam or midazolam is usually tried first. Other barbiturates only have an anticonvulsant effect at anaesthetic doses.

[edit] Benzodiazepines

Main article: Benzodiazepines

The benzodiazepines are a class of drugs with hypnotic, anxiolytic, anticonvulsive, amnestic and muscle relaxant properties. Benzodiazepines act as a central nervous system depressant. The relative strength of each of these properties in any given benzodiazepine varies greatly and influences the indications for which it is prescribed. Long-term use can be problematic due to the development of tolerance to the anticonvulsant effects and dependency.[6][7][8][9] Of the many drugs in this class, only a few are used to treat epilepsy:

The following benzodiazepines are used to treat status epilepticus:

  • Diazepam (1963). Can be given rectally by trained care-givers.
  • Midazolam (N/A). Increasingly being used as an alternative to diazepam. This water-soluble drug is squirted into the side of the mouth but not swallowed. It is rapidly absorbed by the buccal mucosa.
  • Lorazepam (1972). Given by injection in hospital.

Nitrazepam, temazepam, and especially nimetazepam are powerful anticonvulsant agents, however their use is rare due to an increased incidence of side effects and strong sedative and motor-impairing properties.

[edit] Bromides

Main article: Bromides

  • Potassium bromide (1857). The earliest effective treatment for epilepsy. There would not be a better drug for epilepsy until phenobarbital in 1912. It is still used as an anticonvulsant for dogs and cats.

[edit] Carbamates

Main article: Carbamates

  • Felbamate (1993). This effective anticonvulsant has had its usage severely restricted due to rare but life-threatening side effects.

[edit] Carboxamides

Carbamazepine

Main article: Carboxamides

The following are carboxamides:

  • Carbamazepine (1963). A popular anticonvulsant that is available in generic formulations.
  • Oxcarbazepine (1990). A derivative of carbamazepine that has similar efficacy but is better tolerated and is also available generically.
  • Eslicarbazepine acetate (2009)

[edit] Fatty acids

Main article: Fatty acids

The following are fatty-acids:

Vigabatrin and progabide are also analogs of GABA.

[edit] Fructose derivatives

Main article: Fructose

[edit] Gaba analogs

[edit] Hydantoins

Main article: Hydantoins

The following are hydantoins:

[edit] Oxazolidinediones

Main article: Oxazolidinediones

The following are oxazolidinediones:

[edit] Propionates

Main article: Propionates

[edit] Pyrimidinediones

Main article: Pyrimidinediones

[edit] Pyrrolidines

Main article: Pyrrolidines

[edit] Succinimides

Main article: Succinimides

The following are succinimides:

[edit] Sulfonamides

Main article: Sulfonamides

[edit] Triazines

Main article: Triazines

[edit] Ureas

Main article: Ureas

[edit] Valproylamides (amide derivatives of valproate)

Main article: Amides

[edit] Diet

The ketogenic diet is a strict medically supervised diet that has an anticonvulsant effect. It is typically used in children with refractory epilepsy.

[edit] Devices

The vagus nerve stimulator (VNS) is a device that sends electric impulses to the left vagus nerve in the neck via a lead implanted under the skin. It was FDA approved in 1997 as an adjunctive therapy for partial-onset epilepsy.

[edit] Marketing approval history

The following table lists anticonvulsant drugs together with the date their marketing was approved in the US, UK and France. Data for the UK and France are incomplete. In recent years, the European Medicines Agency has approved drugs throughout the European Union. Some of the drugs are no longer marketed.

Drug Brand US UK France
acetazolamide Diamox 1953-07-2727 July 1953[10] 1988[11]
carbamazepine Tegretol 1974-07-1515 July 1974[12][13] 1965[11] 1963[14]
clobazam Frisium 1979[11]
clonazepam Klonopin/Rivotril 1975-06-044 June 1975[15] 1974[11]
diazepam Valium 1963-11-1515 November 1963[16]
divalproex sodium Depakote 1983-03-1010 March 1983[17]
ethosuximide Zarontin 1960-11-022 November 1960[18] 1955[11] 1962[14]
ethotoin Peganone 1957-04-2222 April 1957[19]
felbamate Felbatol 1993-07-2929 July 1993[20]
fosphenytoin Cerebyx 1996-08-055 August 1996[21]
gabapentin Neurontin 1993-12-3030 December 1993[22] 1993-05May 1993[11][14] 1994-10October 1994[14]
lamotrigine Lamictal 1994-12-2727 December 1994[23] 1991-10October 1991[11][14] 1995-05May 1995[14]
levetiracetam Keppra 1999-11-3030 November 1999[24] 2000-09-2929 September 2000[11][25] 2000-09-2929 September 2000[25]
mephenytoin Mesantoin 1946-10-2323 October 1946[26]
metharbital Gemonil 1952[27][28]
methsuximide Celontin 1957-02-088 February 1957[29]
methazolamide Neptazane 1959-01-2626 January 1959[30]
oxcarbazepine Trileptal 2000-01-1414 January 2000[31] 2000[11]
phenobarbital 1912[11] 1920[14]
phenytoin Dilantin/Epanutin 1938[14][32] 1938[11] 1941[14]
phensuximide Milontin 1953[33][34]
pregabalin Lyrica 2004-12-3030 December 2004[35] 2004-07-066 July 2004[11][36] 2004-07-066 July 2004[36]
primidone Mysoline 1954-03-088 March 1954[37] 1952[11] 1953[14]
sodium valproate Epilim 1977-12December 1977[14] 1967-06June 1967[14]
stiripentol Diacomit 2001-12-055 December 2001[38] 2001-12-055 December 2001[38]
tiagabine Gabitril 1997-09-3030 September 1997[39] 1998[11] 1997-11November 1997[14]
topiramate Topamax 1996-12-2424 December 1996[40] 1995[11]
trimethadione Tridione 1946-01-2525 January 1946[41]
valproic acid Depakene/Convulex 1978-02-2828 February 1978[42] 1993[11]
vigabatrin Sabril 2009-08-2121 August 2009[43] 1989[11]
zonisamide Zonegran 2000-03-2727 March 2000[44] 2005-03-1010 March 2005[11][45] 2005-03-1010 March 2005[45]

[edit] See also

[edit] References

  1. ^ Loring, David W (1 September 2005). "Cognitive Side Effects of Antiepileptic Drugs in Children". Psychiatric Times XXII (10). http://www.psychiatrictimes.com/showArticle.jhtml?articleID=171201519. 
  2. ^ Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004 Jul;5(7):553-564. PMID 15208697
  3. ^ Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: a2d, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-352. PMID 18590620
  4. ^ Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007 Jan;4(1):18-61. PMID 17199015
  5. ^ a b c Abou-Khalil BW (2007). "Comparative monotherapy trials and the clinical treatment of epilepsy". Epilepsy currents / American Epilepsy Society 7 (5): 127–9. doi:10.1111/j.1535-7511.2007.00198.x. PMID 17998971. 
  6. ^ Browne TR (May 1976). "Clonazepam. A review of a new anticonvulsant drug". Arch Neurol 33 (5): 326–32. PMID 817697. 
  7. ^ Isojärvi, JI; Tokola RA (December 1998). "Benzodiazepines in the treatment of epilepsy in people with intellectual disability". J Intellect Disabil Res 42 (1): 80–92. PMID 10030438. 
  8. ^ Tomson T; Svanborg E, Wedlund JE (May-Jun 1986). "Nonconvulsive status epilepticus: high incidence of complex partial status". Epilepsia 27 (3): 276–85. doi:10.1111/j.1528-1157.1986.tb03540.x. PMID 3698940. 
  9. ^ Djuric, M; Marjanovic B, Zamurovic D (May-Jun 2001). "[West syndrome--new therapeutic approach]". Srp Arh Celok Lek 129 (1): 72–7. PMID 15637997. 
  10. ^ NDA 008943
  11. ^ a b c d e f g h i j k l m n o p q r Epilepsy Action: Druglist. Retrieved on 1 November 2007.
  12. ^ NDA 016608 (Initial approval on 11 March 1968 was for trigeminal neuralgia.)
  13. ^ Schain, Richard J. (1 March 1978). "Pediatrics—Epitomes of Progress: Carbamazepine (Tegretol) in the Treatment of Epilepsy". Western Journal of Medicine 128 (3): 231–232. PMID 18748164. PMC 1238063. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1238063. Retrieved 14 March 2007. 
  14. ^ a b c d e f g h i j k l m Loiseau, Pierre Jean-Marie (June 1999). "Clinical Experience with New Antiepileptic Drugs: Antiepileptic Drugs in Europe" (PDF). Epilepsia 40 (Suppl 6): S3–8. doi:10.1111/j.1528-1157.1999.tb00925.x. PMID 10530675. http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1528-1157.1999.tb00925.x. Retrieved 26 March 2007. 
  15. ^ NDA 017533
  16. ^ NDA 013263
  17. ^ NDA 018723
  18. ^ NDA 012380
  19. ^ NDA 010841
  20. ^ NDA 020189
  21. ^ NDA 020450
  22. ^ NDA 020235
  23. ^ NDA 020241
  24. ^ NDA 021035
  25. ^ a b EPAR: Keppra. Retrieved on 1 November 2007.
  26. ^ NDA 006008
  27. ^ NDA 008322
  28. ^ Dodson, W. Edwin; Giuliano Avanzini; Shorvon, Simon D.; Fish, David R.; Emilio Perucca (2004). The treatment of epilepsy. Oxford: Blackwell Science. xxviii. ISBN 0-632-06046-8. 
  29. ^ NDA 010596
  30. ^ NDA 011721
  31. ^ NDA 021014
  32. ^ NDA 008762 (Marketed in 1938, approved 1953)
  33. ^ NDA 008855
  34. ^ Kutt, Henn; Resor, Stanley R. (1992). The Medical treatment of epilepsy. New York: Dekker. pp. 385. ISBN 0-8247-8549-5.  (first usage)
  35. ^ NDA 021446
  36. ^ a b EPAR: Lyrica Retrieved on 1 November 2007.
  37. ^ NDA 009170
  38. ^ a b EPAR: Diacomit. Orphan designation: 5 December 2001, full authorisation: 4 January 2007 Retrieved on 1 November 2007.
  39. ^ NDA 020646
  40. ^ NDA 020505
  41. ^ NDA 005856
  42. ^ NDA 018081
  43. ^ Lundbeck Press Release
  44. ^ NDA 020789
  45. ^ a b EPAR: Zonegran. Retrieved on 1 November 2007

[edit] External links

v • d • e
Anticonvulsants (N03)
GABAA receptor agonist
Other GABA agents
Carbonic anhydrase inhibitor
Channel blockers
Primarily sodium
Primarily calcium
Unknown/ungrouped
Indirect GABA agents
Unknown/multiple/
unsorted
#WHO-EM. ‡Withdrawn from market. CLINICAL TRIALS: †Phase III. §Never to phase III
v • d • e
Pharmacology: Major drug groups
Gastrointestinal tract/metabolism (A)
Blood and blood forming organs (B)
Cardiovascular system (C)
Skin (D)
Genitourinary system (G)
Endocrine system (H)
Infections and infestations (J, P, QI)
Malignant disease (L01-L02)
Immune disease (L03-L04)
Muscles, bones, and joints (M)
Brain and nervous system (N)
Respiratory system (R)
Sensory organs (S)
Other ATC (V)
Retrieved from "http://en.wikipedia.org/wiki/Anticonvulsant"

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Anticonvulsant".

Need A Valium Attorney?

First Name Last Name Email Address State
Has Your Health Been Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Do you need a District of Columbia Valium attorney? Contact one of our District of Columbia Valium attorneys now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Valium Case - Submit Your Information Below

Do you need legal assistance with your Valium case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * DrugWatch: Valium Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.